<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptor-γ coactivator-1α (<z:chebi fb="6" ids="26336">PGC</z:chebi>-1α) has been shown to influence energy metabolism </plain></SENT>
<SENT sid="1" pm="."><plain>Hence, we explored a strategy to target <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α expression to treat <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndromes</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We developed a high-throughput screening assay that uses the human <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α promoter to drive expression of luciferase </plain></SENT>
<SENT sid="3" pm="."><plain>The effects of lead compound stimulation on <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α expression in muscle cells and hepatocytes were investigated in vitro and in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>A novel small molecule, ZLN005, led to changes in <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels, <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, and fatty acid oxidation in L6 myotubes </plain></SENT>
<SENT sid="5" pm="."><plain>Activation of <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase was involved in the induction of <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α expression </plain></SENT>
<SENT sid="6" pm="."><plain>In diabetic db/db mice, <z:hpo ids='HP_0011010'>chronic</z:hpo> administration of ZLN005 increased <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α and downstream gene transcription in skeletal muscle, whereas hepatic <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α and gluconeogenesis genes were reduced </plain></SENT>
<SENT sid="7" pm="."><plain>ZLN005 increased fat oxidation and improved the <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, <z:chebi fb="1" ids="15361">pyruvate</z:chebi> tolerance, and insulin sensitivity of diabetic db/db mice </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0003074'>Hyperglycemia</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> also were ameliorated after treatment with ZLN005 </plain></SENT>
<SENT sid="9" pm="."><plain>Our results demonstrated that a novel small molecule selectively elevated the expression of <z:chebi fb="6" ids="26336">PGC</z:chebi>-1α in myotubes and skeletal muscle and exerted promising therapeutic effects for treating type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>